← All trials
NCT06355180
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Apr 9, 2024
- Last posted
- Apr 9, 2024
- Enrollment
- 340
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- The Second People's Hospital of Dali Bai Autonomous PrefectureCollaborator
- Capital Medical UniversitySponsor investigator
- Capital Medical UniversityOfficial
- Wuhu Fourth People's HospitalCollaborator
- Inner Mongolia Autonomous Region Center for Diseases Prevention and Control (IMCDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.